Cancer care in India has reached a critical inflection point. According to the ICMR National Institute of Cancer Prevention and Research, over 700,000 new patients are registered annually, a staggering figure compounded by a reported death toll of approximately 550,000. With a 2022 incidence rate of 100.4 per 100,000 population, these statistics underscore a stark reality: cancer is a rapidly escalating public health crisis that demands immediate, systemic intervention.

Bridging the Urban-Rural Divide

Currently, the burden of advanced oncology is largely carried by private stalwarts such as Apollo Hospitals, HCG Hospitals, and specialized centres like the Rajiv Gandhi Cancer Institute. While these institutions offer world-class care, their footprint is predominantly limited to Tier 1 urban hubs. To truly democratize cancer survival, India’s healthcare system must penetrate Tier 2 and Tier 3 cities, ensuring that accessibility and affordability are not dictated by geography. Currently, the Linear Accelerator Count (LINAC) in India should be around 4000 to support the overall cancer concerned population. However, the actual count is closer to 1000, showing a sharp contrast in the need and requirement of cancer.

The Economics of Infrastructure

Expanding this reach requires a pragmatic approach to the massive capital outlay involved. A single LINAC can cost between ₹25-30 crore, a figure that excludes the additional cost required for MRI, PET, and CT imaging suites. The government-mandated tariff rates under the Ayushman Bharat scheme have been calculated such that hospital operators get fair reimbursement. For instance, a chemotherapy cycle for various organs (such as CA Breast) is priced between ₹14,800 and ₹27,600 for Tier 1 and 2 cities, while Tier 3 rates range from ₹13,000 to ₹23,400. Moreover, Head and Neck oncology treatments are standardized across all three tiers, ranging from ₹8,500 to ₹16,500. Radiation Oncology packages including 20 fractions in Tier 1 cities are approximately ₹91,000 to ₹1,17,000. Although these rates contribute to the economic feasibility for hospital operators, further financial support remains essential to ensure long-term sustainability & high quality care.

To mitigate these barriers, the government must incentivize private investment through strategic intervention:

• Public-Private Partnerships (PPPs): Utilizing PPP models to bridge infrastructure gaps by providing land at subsidized rates or retrofitting underused public buildings.
• Strategic Placement: Ensuring new units are located in high-accessibility zones to foster vibrant healthcare ecosystems.
• Operational Support: Creating a policy environment where private operators feel empowered to expand into remote regions.

Human Capital and Policy Momentum

Infrastructure alone is insufficient without a specialized workforce. There is an urgent need to train and up-skill healthcare professionals including radiation therapists, oncology nurses, and PET/MRI technologists. Elevating the proficiency of these "allied health" workers not only improves patient outcomes and equipment efficiency but also enhances job satisfaction within the sector. The recent Union Budget 2026-27 announcement signaled a positive shift, offering basic customs duty exemptions on 17 essential cancer drugs and funding for upgrading emergency care in district hospitals and launching new trauma centres. Public at large can benefit plenty from this PPP Model as Private Players bring in their operational efficiency, banking upon the investment made by public sector and MedTech Industry also can contribute as well. Moreover, this shall lead to patients consulting quality doctors and may see a rise in private cases. 

These are vital first steps, but the ultimate goal remains a holistic, nationwide system where specialized care is a right, not a luxury.